Literature DB >> 23396165

microRNAs in liver disease: from diagnostics to therapeutics.

Kenji Takahashi1, Irene Yan, Hui-Ju Wen, Tushar Patel.   

Abstract

There is a need to identify effective biomarkers for diagnosis, prognosis and prediction of treatment efficacy for many liver diseases such as hepatocellular cancer, and chronic viral hepatitis. The identification of disease-specific alterations in microRNA expression and the ability to detect microRNAs in the circulation provide the basis for identifying novel clinically effective treatments and biomarkers. Knowledge regarding miRNA in human liver disease may eventually lead to serum or tissue biomarkers with clinical utility. A selection of relevant studies is reviewed. There are major challenges that need to be addressed prior to clinical application such as the need for careful validation of diagnostic miRNA candidates in well described clinical cohorts, and technical issues such as quantitation and standardization of assays. The rapid progress in therapeutic interventions using miRNA based strategies for chronic hepatitis C and hepatocellular cancer provides optimism for novel approaches that will build on the existing and emerging knowledge regarding miRNA in liver diseases.
Copyright © 2013 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23396165      PMCID: PMC3804836          DOI: 10.1016/j.clinbiochem.2013.01.025

Source DB:  PubMed          Journal:  Clin Biochem        ISSN: 0009-9120            Impact factor:   3.281


  84 in total

1.  MicroRNA profiling identifies miR-29 as a regulator of disease-associated pathways in experimental biliary atresia.

Authors:  Nicholas J Hand; Amber M Horner; Zankhana R Master; LaTasha A Boateng; Claire LeGuen; Marina Uvaydova; Joshua R Friedman
Journal:  J Pediatr Gastroenterol Nutr       Date:  2012-02       Impact factor: 2.839

2.  Hepatocyte-derived microRNAs as serum biomarkers of hepatic injury and rejection after liver transplantation.

Authors:  Waqar R R Farid; Qiuwei Pan; Adriaan J P van der Meer; Petra E de Ruiter; Vedashree Ramakrishnaiah; Jeroen de Jonge; Jaap Kwekkeboom; Harry L A Janssen; Herold J Metselaar; Hugo W Tilanus; Geert Kazemier; Luc J W van der Laan
Journal:  Liver Transpl       Date:  2012-03       Impact factor: 5.799

3.  MicroRNA genes are transcribed by RNA polymerase II.

Authors:  Yoontae Lee; Minju Kim; Jinju Han; Kyu-Hyun Yeom; Sanghyuk Lee; Sung Hee Baek; V Narry Kim
Journal:  EMBO J       Date:  2004-09-16       Impact factor: 11.598

4.  Correlation between microRNA expression levels and clinical parameters associated with chronic hepatitis C viral infection in humans.

Authors:  Rebecca T Marquez; Sarmistha Bandyopadhyay; Erik B Wendlandt; Kathy Keck; Brandon A Hoffer; Michael S Icardi; Randolph N Christensen; Warren N Schmidt; Anton P McCaffrey
Journal:  Lab Invest       Date:  2010-07-12       Impact factor: 5.662

5.  Alterations in microRNA expression profile in HCV-infected hepatoma cells: involvement of miR-491 in regulation of HCV replication via the PI3 kinase/Akt pathway.

Authors:  Hisashi Ishida; Tomohide Tatsumi; Atsushi Hosui; Takatoshi Nawa; Takahiro Kodama; Satoshi Shimizu; Hayato Hikita; Naoki Hiramatsu; Tatsuya Kanto; Norio Hayashi; Tetsuo Takehara
Journal:  Biochem Biophys Res Commun       Date:  2011-07-23       Impact factor: 3.575

6.  miR-373 negatively regulates methyl-CpG-binding domain protein 2 (MBD2) in hilar cholangiocarcinoma.

Authors:  Yongjun Chen; Jian Luo; Rui Tian; Huawen Sun; Shengquan Zou
Journal:  Dig Dis Sci       Date:  2010-11-18       Impact factor: 3.199

7.  Differential expression of microRNA species in human gastric cancer versus non-tumorous tissues.

Authors:  Junming Guo; Ying Miao; Bingxiu Xiao; Rong Huan; Zhen Jiang; Dan Meng; Yanjun Wang
Journal:  J Gastroenterol Hepatol       Date:  2008-11-03       Impact factor: 4.029

8.  Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers.

Authors:  George Adrian Calin; Cinzia Sevignani; Calin Dan Dumitru; Terry Hyslop; Evan Noch; Sai Yendamuri; Masayoshi Shimizu; Sashi Rattan; Florencia Bullrich; Massimo Negrini; Carlo M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-18       Impact factor: 11.205

9.  Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma.

Authors:  Laura Gramantieri; Manuela Ferracin; Francesca Fornari; Angelo Veronese; Silvia Sabbioni; Chang-Gong Liu; George A Calin; Catia Giovannini; Eros Ferrazzi; Gian Luca Grazi; Carlo M Croce; Luigi Bolondi; Massimo Negrini
Journal:  Cancer Res       Date:  2007-07-01       Impact factor: 12.701

10.  Hepatitis C virus proteins modulate microRNA expression and chemosensitivity in malignant hepatocytes.

Authors:  Chiara Braconi; Nicola Valeri; Pierluigi Gasparini; Nianyuan Huang; Cristian Taccioli; Gerard Nuovo; Tetsuro Suzuki; Carlo Maria Croce; Tushar Patel
Journal:  Clin Cancer Res       Date:  2010-01-26       Impact factor: 12.531

View more
  23 in total

1.  Serum microRNAs explain discordance of non-alcoholic fatty liver disease in monozygotic and dizygotic twins: a prospective study.

Authors:  Amir Zarrinpar; Shakti Gupta; Mano R Maurya; Shankar Subramaniam; Rohit Loomba
Journal:  Gut       Date:  2015-05-22       Impact factor: 23.059

Review 2.  MicroRNA and hepatitis C virus--challenges in investigation and translation: a review of the literature.

Authors:  Paul Ravi Waldron; Mark Holodniy
Journal:  Diagn Microbiol Infect Dis       Date:  2014-06-05       Impact factor: 2.803

3.  Androgen receptor in hepatocarcinogenesis: Recent developments and perspectives.

Authors:  Y E Tian; X U Xie; Yao Lin; Guang Tan; W U Zhong
Journal:  Oncol Lett       Date:  2015-03-10       Impact factor: 2.967

Review 4.  Epigenetic Aspects and Prospects in Autoimmune Hepatitis.

Authors:  Albert J Czaja
Journal:  Front Immunol       Date:  2022-06-30       Impact factor: 8.786

5.  Missing Causality and Heritability of Autoimmune Hepatitis.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2022-10-19       Impact factor: 3.487

Review 6.  Cholangiocarcinoma.

Authors:  Nataliya Razumilava; Gregory J Gores
Journal:  Lancet       Date:  2014-02-26       Impact factor: 79.321

Review 7.  Emerging insights into the role of microRNAs in the pathogenesis of cholangiocarcinoma.

Authors:  Hiroaki Haga; Irene Yan; Kenji Takahashi; Joseph Wood; Tushar Patel
Journal:  Gene Expr       Date:  2014

Review 8.  Diagnostic and Prognostic Value of MicroRNA in Viral Diseases.

Authors:  Eeva Auvinen
Journal:  Mol Diagn Ther       Date:  2017-02       Impact factor: 4.074

Review 9.  Long noncoding RNA in liver diseases.

Authors:  Kenji Takahashi; Irene Yan; Hiroaki Haga; Tushar Patel
Journal:  Hepatology       Date:  2014-06-20       Impact factor: 17.425

Review 10.  Targeted therapies for extrahepatic cholangiocarcinoma: preclinical and clinical development and prospects for the clinic.

Authors:  Massimiliano Cadamuro; Alberto Lasagni; Angela Lamarca; Laura Fouassier; Maria Guido; Samantha Sarcognato; Enrico Gringeri; Umberto Cillo; Mario Strazzabosco; Jose Jg Marin; Jesus M Banales; Luca Fabris
Journal:  Expert Opin Investig Drugs       Date:  2021-02-23       Impact factor: 6.206

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.